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patients treated with the multi-kinase
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Abstract
Background: Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase
(BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET),
inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors. A side effect of sorafenib is the
occurrence of cutaneous squamous tumors.
Case presentation: Here we describe three patients with a history of sorafenib treatment for advanced radioactive
iodine refractory papillary thyroid cancer (two with a BRAF c.1799 T > A and one carrying a rare c.1799-1801het_delTGA
mutation) who presented with secondary non-cutaneous lesions. The first patient was diagnosed with a squamous cell
carcinoma (SCC) of the tongue, the second patient with a primary adenocarcinoma of the lung, and the third with a
SCC originating from the cricoid. Secondary analysis was required to show that the latter two presentations were in
fact recurrent thyroid cancer.
Conclusion: These findings suggest that drugs such as sorafenib may induce metaplasia/clonal divergence of
metastatic thyroid cancer and thus cause diagnostic misclassification. Furthermore, sorafenib is potentially involved in
the tumorigenesis of secondary non-cutaneous SCC. These observations should now be confirmed in larger series of
patients treated with drugs such as sorafenib.
Keywords: Sorafenib, Differentiated thyroid cancer, Squamous cell carcinoma, Squamous differentiation, Clonal
divergence
Background
Sorafenib (BAY-43-9006) is an orally active multikinase
tyrosine kinase inhibitor (TKI) that activates anti-
angiogenic and pro-apoptotic pathways, targeting the B-
type Raf kinase (BRAF), vascular endothelial growth fac-
tor receptors (VEGFR) 1 and 2, and rearranged during
transfection (RET). Sorafenib is widely approved for the
treatment of patients with hepatocellular carcinoma
(HCC) and advanced renal cell carcinoma (RCC) in
well-defined phases of disease. Since June 2015 sorafenib
is also registered for the treatment of patients with thy-
roid cancer by the European Medicines Agency (EMA).
Multiple clinical trials have been conducted in a wide
range of cancers (lung, thyroid, breast, colorectal) using
sorafenib as a single agent or in combination treatment
(www.clinicaltrials.gov).
Recently published results of a phase III trial of sorafe-
nib in patients with advanced radioactive iodine 131-I
(RAI) refractory differentiated thyroid carcinoma (DTC)
showed that sorafenib has clinically relevant antitumor
activity and a generally well-tolerated profile of adverse
events (AEs). The most commonly reported sorafenib-
related AEs in DTC include hand-foot syndrome, hyper-
tension, weight loss, diarrhea and rash [1, 2]. Recent
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reports have also suggested a possible causal link be-
tween sorafenib therapy and the development of cutane-
ous squamous cell carcinomas (SCC) [3–8].
We now describe three patients who received sorafe-
nib during treatment for advanced RAI refractory DTC
and presented with secondary non-cutaneous squamous
lesions.
Materials and methods
The presence of somatic DNA mutations including
BRAF (V600E and V600K), KRAS (codon 12/13), and
PIK3CA (exons 9 and 20) were determined by quantita-
tive real-time PCR (qPCR) with hydrolysis probes (Cus-
tom TaqMan® Assay Design Tool, Applied Biosystems,
Nieuwerkerk a/d IJssel, NL), and when indicated, by
standard Sanger DNA sequencing on an ABI 3739 auto-
mated sequencer (Applied Biosystems, Foster City, CA,
USA) [9]. Tissues were microdissected to enrich for
tumor cells and tumor areas were selected based on the
analysis of a hematoxylin eosin (HE)-stained tissue slide.
Tumor DNA was subsequently isolated using the
Nucleospin Tissue kit (Marcherey-Nagel, Bethlehem,
PA, USA) according to manufacturer’s protocol.
Case presentation
Patient 1
A 67-year-old female was diagnosed with a well differen-
tiated papillary thyroid carcinoma (PTC, BRAF
c.1799 T > A; p.V600E mutation positive), stage
T2N0M0, in 1989. She underwent a total thyroidectomy
and RAI ablation therapy. Local recurrent disease was
diagnosed ten years later and treated with a left-sided
modified radical neck dissection, followed by RAI ther-
apy. The post-therapy scintigraphy showed no RAI up-
take. Six years later routine follow-up with computed
tomography (CT) identified metastatic disease with mul-
tiple lung lesions, the largest measuring 5 mm (2005). A
total body scintigraphy after RAI therapy showed no up-
take of RAI despite elevated thyroglobulin levels (68 ug/
l), indicating RAI refractory disease. Due to the progres-
sion of disease two years later (2007) the patient
received sorafenib (2 x 400 mg/day initially, reduced to
1 x 200 mg/day after 6 months) in the context of a phase
II study [2, 10]. Follow-up showed stable disease accord-
ing to the Response Evaluation Criteria in Solid Tu-
mours (RECIST) 1.0 [11]. Thirty-nine months after
starting sorafenib, with ongoing stable disease, the pa-
tient stopped therapy mainly due to diarrhea.
After starting sorafenib treatment, the patient devel-
oped several skin lesions (for a summary see Table 1).
Furthermore, within 2 months of beginning sorafenib
therapy the patient developed left-sided tongue com-
plaints, originally histologically diagnosed and treated as
mucosal hyperplasia with Candida albicans infection.
The symptoms persisted however and eventually led,
46 months after the initial complaints, to the diagnosis
of a T2N2cM0 functional irresectable SCC of the tongue
(thyroid transcription factor (TTF)-1 and thyroglobulin
immunohistochemically negative; BRAF p.V600E nega-
tive) with ipsi-lateral lymph node metastasis (Fig. 1).
Despite chemo-radiation therapy with 7 rounds of cis-
platin, the patient died 5 months after diagnosis of the
SSC.
Patient 2
The second (male) patient was diagnosed with a
T4N1Mx PTC without squamous metaplasia (positive
for the rare BRAF mutation c.1799-1801het_delTGA,
Fig. 2) at the age 67 [12–14]. He underwent a total thy-
roidectomy with a right-sided lymph node dissection,
followed by RAI ablation therapy in 2001. In 2004 the
patient had recurrent disease, and a bilateral para-
tracheal lymph node dissection was performed. A year
later he presented with local recurrent disease and the
presence of multiple pulmonary metastases. A whole
body scintigraphy after RAI therapy showed no RAI up-
take, while thyroglobulin levels were 133 ug/l, thus dem-
onstrating RAI refractory disease. In 2007, the patient
was referred to our hospital for inclusion in a phase II
trial and received sorafenib 400 mg twice daily [2, 10].
Despite initial stable disease, the patient became pro-
gressive under sorafenib after 19 months of therapy. The
Table 1 Summary of lesions seen in patient 1 after starting sorafenib treatment November 2007
Date Lesion
February 2008 SCC on the backCandida infection of the tongue
April 2008 Reactive epithelial skin lesion on the back without obvious atypiaLeukokeratosis of the tongue with atypia and inflammation
June 2008 Lesion with inverted follicular keratosis on the lower left leg
September 2009 Trichilemmoma of the nose
March 2010 Irritated verruca seborrhoica upper right leg
May 2010 Reactive epithelial hyperplasia of the tongue due to a candida infection
August 2011 Invasive squamous cell carcinoma of the tongueMultiple lymph node metastasis of the SCC in the neck region
December 2011 SCC lymph node metastasis in the left axilla
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patient was subsequently enrolled in a clinical study
(RAD001, www.clinicaltrials.gov CRAD001CNL08T) to
determine the efficacy of everolimus in patients with
progressive irresectable recurrent or metastatic differen-
tiated, undifferentiated (anaplastic) and medullary thy-
roid carcinoma. The patient ceased everolimus therapy
18 months later due to progressive disease. A CT
showed a new pulmonary lesion and a number of (non)-
target lesions according to RECIST 1.0 [11]. Since all
conventional or study-based treatment options had been
exhausted, the patient was referred back to his own hos-
pital where he presented 2 months later with progressive
dyspnea due to malignant pleural effusion. A CT showed
multiple bilateral pulmonary metastases and a large right
para-tracheal lesion. Surprisingly, right-sided pleural
fluid cytology elsewhere revealed a primary adenocarcin-
oma of the lung. Immunohistochemistry of embedded
cytological material showed TTF-1 and cytokeratin (CK)
7 positivity and absence of staining for thyroglobulin,
cluster of differentiation (CD) 56 and CK20. Additional
paired box (PAX) 8 and CK19 staining in our institute
were however positive, indicative of metastatic PTC
(Fig. 3). Molecular testing confirmed this diagnosis with
the presence of the previous identified BRAF mutation.
The patient died a month later due to disease progression.
Patient 3
A 60-year-old male was diagnosed with a T2N0M0
poorly differentiated PTC (BRAF c.1799 T > A; V600E
mutation positive) in 2002. The patient was treated by
total thyroidectomy with a left-sided lymph node dissec-
tion, followed by RAI ablation therapy. Three years later
(2005) he presented with multiple pulmonary lesions,
non-RAI avid on whole body scintigraphy after RAI
therapy, and thyroglobulin levels of 127 ug/l. Due to dis-
ease progression in 2008 the patient was included in a
phase II trial (and received 2 x 400 mg sorafenib daily)
[2, 10]. In the first 6 months a partial response was
achieved, which was ongoing until therapy discontinu-
ation 32 months later due to complaints of diarrhea and
hand-foot syndrome. A CT four months after therapy
discontinuation still showed an ongoing partial response
per RECIST 1.0 [11]. However, seven weeks later the pa-
tient presented with respiratory failure due to airway ob-
struction. A large tumor originating from the cricoid
was visible on CT scan. Initial histological examination
elsewhere concluded that the lesion was a SCC originat-
ing from the cricoid. Revision of the tumor showed a le-
sion with squamous differentiation (Fig. 4). Although
P63 staining (indicative of squamous differentiation) was
positive in a subset of cells, immunohistochemistry also
showed TTF-1 and thyroglobulin to be focally positive,
indicative of a PTC recurrence. Surprisingly, the BRAF
mutation present in the primary tumor was not recov-
ered from this tumor, possibly suggesting clonal diver-
gence after sorafenib treatment. Given the fact that local
treatment was not an option the patient received a
Fig. 1 Lymph node metastasis of the SCC of the tongue in patient 1. HE
staining of a fine needle aspirate (FNA) of a cervical lymph node using a
standard embedding procedure of cytology material and histologic
processing. Atypical squamous cells with (para-)keratotic horn were seen,
indicative of metastasized SCC
Fig. 2 BRAF DNA sequencing. Identification of a rare BRAF mutation c.1799-1801het_delTGA
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tracheal stoma followed by radiotherapy. He died
8 months later due to tumor progression.
Discussion
The cases described here present three interesting obser-
vations. Firstly, (although lacking proven causality) our
demonstration of a primary tongue carcinoma that arose
after long-term sorafenib treatment suggests that treat-
ment with the multikinase inhibitor sorafenib may cause
other effects additional to squamous skin lesions [3–8].
However, since patient 2 was subsequently treated with
everolimus, a combined effect of sorafenib and everoli-
mus cannot be ruled out. Secondly, we note that meta-
plastic changes or clonal divergence can result in the
misdiagnosis of recurrences of thyroid cancer. Indeed,
clonal divergence at the molecular level might be an as-
pect of PTC with BRAF c.1799 T > A; p.V600E muta-
tions. Thirdly, we identified a rare BRAF mutation,
c.1799-1801het_delTGA, which will be missed by the
allele-specific assays currently in use in daily practice in
many laboratories.
It has been proposed that BRAF kinase inhibitors can
stimulate proliferation in cells lacking mutant BRAF via
a paradoxical activation of RAF-MEK-ERK1/2 pathway
signaling in the presence of upstream activation of RAS,
thus possibly explaining the development of cutaneous
SCC [3–8]. This hypothesis was supported by a study
that analyzed oncogenic mutations in cutaneous SCCs in
melanoma patients treated with the BRAF inhibitor
vemurafenib. This study found that 13 out of 21 tumors
harbored a RAS mutation [15]. Furthermore, there are
several reports on patients treated with a BRAF inhibitor
who developed secondary tumors. One case has been
described of a patient on vemurafenib treatment for a
melanoma who developed a RAS-mutant leukemia correl-
ating with enhanced extracellular signal-regulated kinases
(ERK) signaling [16]. Another study reports the develop-
ment of four colonic adenomas, one hyperplastic colonic
polyp and six gastric polyps in a patient also treated with
vemurafenib for a melanoma. However, no evidence of
RAS mutations was reported in any of the adenomas iden-
tified in this patient [17]. In addition, progression of a pre-
viously present KRAS mutated colon carcinoma due to
stimulated ERK signaling was reported in a patient with a
melanoma treated with dabrafenib [18]. A similar molecu-
lar explanation might be relevant to the cases we now
present, although the presence of RAS mutations was not
completely tested in the lesions with squamous metaplasia.
Fig. 3 Pathological analysis of pleural effusion in patient 2. FNA of a right-sided pleural effusion after embedding and histological processing. a HE; b: TTF1
immunohistochemistry (IHC); c: PAX8 IHC
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Conclusions
In summary, we described three patients with ad-
vanced RAI refractory DTC and a history of sorafenib
treatment who presented with a secondary non-
cutaneous lesion. The first patient was diagnosed with
a SCC of the tongue; the remaining two patients had
recurrent disease with altered morphology and mo-
lecular biology suggesting clonal divergence, initial di-
agnosed as a primary adenocarcinoma and SCC,
originating from the lung and cricoid respectively. Al-
though the possibility that these tumors were already
present in the form of micrometastases prior to soraf-
enib treatment cannot be excluded, these observations
are quite remarkable. It is therefore important that a
pathologist is familiar with the patient’s medical his-
tory and treatment and that the possibility of unusual
presentation is kept in mind when considering sec-
ondary lesions.
Consent
Written informed consent was obtained from the pa-
tients for publication of this case report and any accom-
panying images. A copy of the written consents is
available for review by the Editor of this journal.
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Fig. 4 PTC recurrence in the laryngeal cricoid of patient 3. In a biopsy from the laryngeal cricoid solid sheets of tumor cells were seen with focal
keratinisation. Panel a shows the HE stained tissue. Immunohistochemical analysis of TTF-1 (panel b) and P63 (Panel c) is shown. A large propor-
tion of the cells stained positive for P63, supporting the squamous features. However, there was a fraction a cells that stained moderately positive
for TTF-1 (thick arrow in panel b), partly overlapping with P63 positivity (thin arrow in panel c). Thyroglobulin also stained focally positive (not
shown). Due to the TTF-1 and thyroglobulin positivity, we favoured the diagnosis of recurrent papillary thyroid cancer with remarkable squamous
metaplasia over a primary laryngeal squamous carcinoma
Schneider et al. BMC Cancer  (2016) 16:31 Page 5 of 6
References
1. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib
in radioactive iodine-refractory, locally advanced or metastatic differentiated
thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet [epub
ahead of print].
2. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW. Long-term
analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine
refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur
J Endocrinol. 2012;167(5):643–50.
3. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, et al.
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation
and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res.
2012;18(1):263–72.
4. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM.
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses
associated with sorafenib. Clin Genitourin Cancer. 2009;7(1):20–3.
5. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, et al.
Multiple squamous cell carcinomas of the skin after therapy with sorafenib
combined with tipifarnib. Arch Dermatol. 2008;144(6):779–82.
6. Raymond AK, Puri PK, Selim MA, Tyler DS, Nelson KC. Regional squamous
cell carcinomas following systemic sorafenib therapy and isolated limb
infusion for regionally advanced metastatic melanoma of the limb. Arch
Dermatol. 2010;146(12):1438–9.
7. Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type
squamous cell carcinomas in patients taking sorafenib for the treatment of
solid tumors. Dermatol Surg. 2009;35(11):1766–70.
8. Williams VL, Cohen PR, Stewart DJ. Sorafenib-induced premalignant and
malignant skin lesions. Int J Dermatol. 2011;50(4):396–402.
9. van Eijk R, van Puijenbroek M, Chhatta AR, Gupta N, Vossen RH, Lips EH,
et al. Sensitive and specific KRAS somatic mutation analysis on whole-
genome amplified DNA from archival tissues. J Mol Diagn. 2010;12:27–34.
10. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom
H, et al. Beneficial effects of sorafenib on tumor progression, but not on
radioiodine uptake, in patients with differentiated thyroid carcinoma.
Eur J Endocrinol. 2009;161:923–31.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
et al. New guidelines to evaluate the response to treatment in solid tumors.
J Natl Cancer Inst. 2009;92:205–16.
12. Lee YW. Peptide nucleic acid clamp polymerase chain reaction reveals a
deletion mutation of the BRAFgene in papillary thyroid carcinoma: A case
report. Exp Ther Med. 2013;6:1550–2.
13. Lee SR, Jung CK, Kim TE, Bae JS, Jung SL, Choi YJ, et al. Molecular
genotyping of follicular variant of papillary thyroid carcinoma correlates
with diagnostic category of fine-needle aspiration cytology: values of RAS
mutation testing. Thyroid. 2013;11:1416–22.
14. Jang MA, Lee ST, Oh YL, Kim SW, Chung JH, Ki CS, et al. Identification of a
rare 3 bp BRAF gene deletion in a thyroid nodule by mutant enrichment
with 3'-modified oligonucleotides polymerase chain reaction. Ann Lab Med.
2012;3:238–41.
15. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations
in cutaneous squamous-cell carcinomas in patients treated with BRAF
inhibitors. N Engl J Med. 2012;366:207–15.
16. Callahan MK1, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T,
et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment.
N Engl J Med. 2012;367:2316–21.
17. Chapman P, Metz D, Sepulveda AR. Development of colonic adenomas and
gastric polyps in BRAF mutant melanoma patients treated with
vemurafenib. Pigment Cell Melanoma Res. 2012;25:847.
18. Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ. BRAF inhibitor-
driven tumor proliferation in a KRAS-mutated colon carcinoma is not
overcome by MEK1/2 inhibition. J Clin Oncol. 2013;31:e448–51. •  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Schneider et al. BMC Cancer  (2016) 16:31 Page 6 of 6
